![Ken Lu](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Ken Lu
Direktor/Vorstandsmitglied bei
GLOBAL CORD BLOOD CORPORATION
Profil
Ken Lu is the founder of APAC Capital Advisors Ltd. founded in 2004.
He is currently an Independent Non-Executive Director at Global Cord Blood Corp.
since 2009 and a Managing Partner at Fort Hill Capital Ltd. He previously worked as a Director at China Biologic Products, Inc., Managing Director at Seres Asset Management Ltd., and Head-China Research at Credit Suisse First Boston (Hong Kong) Ltd. from 2001 to 2004.
Dr. Lu holds a doctorate degree from the University of California, Los Angeles, an undergraduate degree from Peking University, and a graduate degree from Brigham Young University.
Aktive Positionen von Ken Lu
| Unternehmen | Position | Beginn |
|---|---|---|
| GLOBAL CORD BLOOD CORPORATION | Direktor/Vorstandsmitglied | 30.06.2009 |
Fort Hill Capital Ltd. | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Ken Lu
| Unternehmen | Position | Ende |
|---|---|---|
APAC Capital Advisors Ltd. | Gründer | 01.01.2010 |
Credit Suisse First Boston (Hong Kong) Ltd.
 Credit Suisse First Boston (Hong Kong) Ltd. Financial ConglomeratesFinance Provides investment & financial services | Corporate Officer/Principal | 01.05.2004 |
China Biologic Products, Inc.
 China Biologic Products, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and distributes plasma-based pharmaceutical products and other biological substances | Direktor/Vorstandsmitglied | - |
Seres Asset Management Ltd.
 Seres Asset Management Ltd. Investment ManagersFinance Seres is a global investment management firm that specializes in equity, fixed income and derivative strategies. The firm aims to identify early-stage growth opportunities, taking advantage of potential valuation correction at the industry or company level given by earnings growth or analyst re-ratings and to exploit informational inefficiencies created by poor coverage and a lack of market consensus in unpopular and under researched names. | Corporate Officer/Principal | - |
Ausbildung von Ken Lu
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
20
Beziehungen ersten Grades
9
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 9 |
|---|---|
Global Cord Blood Corp.
 Global Cord Blood Corp. Medical/Nursing ServicesHealth Services Provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services | Health Services |
University of California, Los Angeles
 University of California, Los Angeles Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Peking University
 Peking University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Brigham Young University
 Brigham Young University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
APAC Capital Advisors Ltd. | |
China Biologic Products, Inc.
China Biologic Products, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and distributes plasma-based pharmaceutical products and other biological substances | Health Technology |
Credit Suisse First Boston (Hong Kong) Ltd.
Credit Suisse First Boston (Hong Kong) Ltd. Financial ConglomeratesFinance Provides investment & financial services | Finance |
Seres Asset Management Ltd.
Seres Asset Management Ltd. Investment ManagersFinance Seres is a global investment management firm that specializes in equity, fixed income and derivative strategies. The firm aims to identify early-stage growth opportunities, taking advantage of potential valuation correction at the industry or company level given by earnings growth or analyst re-ratings and to exploit informational inefficiencies created by poor coverage and a lack of market consensus in unpopular and under researched names. | Finance |
Fort Hill Capital Ltd. |
